Early Risk of Mortality after Coronary Artery Revascularization in Patients with Left Ventricular Dysfunction and Potential Role of the Wearable Cardioverter Defibrillator
Implantable cardioverter defibrillator (ICD) implantation for prevention of sudden cardiac death is typically deferred for 90 days after coronary revascularization, but mortality may be highest early after cardiac procedures in patients with ventricular dysfunction. We determined mortality risk in post-revascularization patients with left ventricular ejection fraction (LVEF) ≤35% and compared survival to those discharged with a wearable cardioverter defibrillator (WCD).
Methylene Blue to Treat Vasoplegia Due to a Severe Protamine Reaction: A Case Report
A review of the pathophysiologic characteristics associated with vasoplegia and the pharmacodynamics of methylene blue will potentially enable anesthesia providers to utilize this lifesaving drug when needed.
Conduits for Coronary Bypass: Internal Thoracic Artery
Thus widespread adaption of the ITA as the conduit of choice for the anterior descending required another decade and bilateral use is only now expanding to more than 5% of patients in the US and somewhat faster in other countries.
Marfan Syndrome: Correct Diagnosis Can Save Lives
Marfan syndrome is a heritable disorder of the connective tissue that affects many systems of the body. However, the most serious complication in patients with Marfan syndrome is progressive enlargement of the aortic root, which may lead to aortic dissection, rupture, or aortic regurgitation.
Alternative Access in Transcatheter Aortic Valve Implantation: Brachiocephalic Artery Access
The direct brachiocephalic access can be obtained with or without partial upper sternotomy, depending on the anatomy, which should be evaluated by preprocedural angiographic computed tomography scan.
Methylene Blue and Vasoplegia: Who, When, and How
Vasoplegia has been observed in all age groups and in various clinical settings, such as anaphylaxis (including protamine reaction), sepsis, hemorrhagic shock, hemodialysis, and cardiac surgery.
The End Organ Protection in Cardiac Surgery
Mortality and morbidity post cardiac surgery with cardiopulmonary bypass (CPB) remain relative stable over the last decades, while the number of patients with increased co-morbidity and more complex cardiac disease increases.
Perioperative Management of Antithrombotic Therapy in Cardiovascular Patients
In this article, we review some of the general principles involved with perioperative anticoagulation and discuss the perioperative management of patients taking vitamin K antagonists (VKAs), bridging regimens for anticoagulants and antiplatelet agents, and strategies for managing patients on the newer oral anticoagulants.
Thrombin Generation Assay: A New Tool to Predict and Optimize Clinical Outcome in Cardiovascular Patients?
In this review we provide a brief description of the assay and we summarize the principals of previous studies by analyzing the relationship between anticoagulant drugs and TGA.
Preliminary Evidence for Reduced Preoperative Cerebral Blood Flow Velocity as a Risk Factor for Cognitive Decline Three Months after Cardiac Surgery: An Extension Study
This extension study investigated the association between preoperative cerebral blood flow (CBF) velocity and postoperative cognitive decline (POCD) at a three-month follow-up in patients who underwent cardiac surgery.
Veno-Right Ventricular Cannulation Reduces Recirculation in Extracorporeal Membrane Oxygenation
We compared recirculation in veno-right ventricular support with that in conventional veno-venous support and its relationship with pump flow.
The Science behind Percutaneous Hemodynamic Support: A Review and Comparison of Support Strategies
With these goals in mind, the scientific principles that govern hemodynamic effectiveness and myocardial protection as they pertain to acute support devices are reviewed.